Now with 451 kinase assays in the scanMAX assay panel, which will be available for global customers by mid-June 2011, DiscoveRx will continue to offer kinase panel for screening and profiling services.
DiscoveRx president and CEO Pyare Khanna said the company has always believed in investing in innovation, first with PathHunter cell-based and HitHunter biochemical assays utilizing its ß-galactosidase enzyme fragment complementation platform and now with KINOMEscan high-throughput kinase inhibitor and profiling platform.
"Today’s drug discovery efforts demand a high quality, highly differentiated solution portfolio and DiscoveRx is committed to providing this through innovation, quality and service to its customers," Khanna said.
In October 2010, DiscoveRx completed the acquisition of the KINOMEscan division of Ambit Biosciences thereby becoming a solution provider for kinase drug discovery profiling and screening.
DiscoveRx pioneered the use of ß-galactosidase enzyme fragment complementation in biochemical and cell based assays for discovery research in fields of receptor biology, and holds extensive intellectual property in this area.